HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Danshen extract 15,16-dihydrotanshinone I functions as a potential modulator against metabolic syndrome through multi-target pathways.

Abstract
Hypertension is a common complication of type 2 diabetes mellitus (T2DM), and is the main cause for T2DM-associated mortality. Although the stringent control of blood pressure is known to be beneficial in reducing the cardiovascular mortality of T2DM patients, drugs with both anti-hypertensive and anti-hyperglycemic effects are seldom reported. The traditional Chinese medicine danshen has long been used for lowering both blood pressure and blood glucose in T2DM patients, shedding lights on the development of such medication. However, the molecular mechanism and active component remain unclear. Here, we report that the lipophilic component, 15,16-dihydrotanshinone I (DHTH) from danshen potently antagonized both mineralocorticoid and glucocorticoid receptors, and efficiently inhibited the expression of their target genes like Na(+)/K(+) ATPase, glucose 6-phosphatase (G6Pase), and phosphoenolpyruvate carboxykinase (PEPCK). In addition, DHTH increased AMPKalpha phosphorylation and regulated its downstream pathways, including increasing acetyl-CoA carboxylase (ACC) phosphorylation, inhibiting transducer of regulated CREB activity 2 (TORC2) translocation and promoting glucose uptake. Such discovered multi-target effects of DHTH are expected to have provided additional understandings on the molecular basis of the therapeutic effects of danshen against the metabolic syndrome.
AuthorsQiong Liu, Yu Zhang, Zhonghui Lin, Hong Shen, Lili Chen, Lihong Hu, Hualiang Jiang, Xu Shen
JournalThe Journal of steroid biochemistry and molecular biology (J Steroid Biochem Mol Biol) Vol. 120 Issue 4-5 Pg. 155-63 (Jun 2010) ISSN: 1879-1220 [Electronic] England
PMID20380878 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • CRTC2 protein, human
  • Furans
  • Mineralocorticoid Receptor Antagonists
  • Phenanthrenes
  • Quinones
  • Receptors, Glucocorticoid
  • Receptors, Mineralocorticoid
  • Transcription Factors
  • dihydrotanshinone I
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase
  • AMP-Activated Protein Kinases
  • Glucose-6-Phosphatase
  • Carboxy-Lyases
  • Acetyl-CoA Carboxylase
  • Sodium-Potassium-Exchanging ATPase
  • Glucose
Topics
  • 3T3 Cells
  • AMP-Activated Protein Kinases (metabolism)
  • Acetyl-CoA Carboxylase (metabolism)
  • Animals
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase (metabolism)
  • Carboxy-Lyases (genetics)
  • Cell Line
  • Furans
  • Gene Expression (drug effects)
  • Glucose (metabolism)
  • Glucose-6-Phosphatase (genetics)
  • Humans
  • Mice
  • Mineralocorticoid Receptor Antagonists
  • Phenanthrenes (isolation & purification, pharmacology)
  • Quinones
  • Receptors, Glucocorticoid (antagonists & inhibitors, metabolism)
  • Receptors, Mineralocorticoid (metabolism)
  • Salvia miltiorrhiza (chemistry)
  • Signal Transduction (drug effects)
  • Sodium-Potassium-Exchanging ATPase (antagonists & inhibitors, metabolism)
  • Transcription Factors (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: